Undisclosed RNA Immunotherapy
Melanoma
About Epitopea
Epitopea is a private, pre-clinical stage biotech founded in 2020, with dual headquarters in Cambridge, UK, and Montreal, Canada. The company's core innovation is the CryptoMap™ platform, which computationally and experimentally mines the 'dark immunopeptidome' to discover shared tumor antigens derived from aberrant gene expression, enabling the development of off-the-shelf RNA immunotherapies. With a focus on solid tumors like melanoma and NSCLC, Epitopea is building its pipeline and team, recently expanding its Scientific Advisory Board and clinical development capabilities as it accelerates toward the clinic. The company operates as a platform-based therapeutics developer and is currently pre-revenue.
View full company profileAbout Epitopea
Epitopea is a private, pre-clinical stage biotech founded in 2020, with dual headquarters in Cambridge, UK, and Montreal, Canada. The company's core innovation is the CryptoMap™ platform, which computationally and experimentally mines the 'dark immunopeptidome' to discover shared tumor antigens derived from aberrant gene expression, enabling the development of off-the-shelf RNA immunotherapies. With a focus on solid tumors like melanoma and NSCLC, Epitopea is building its pipeline and team, recently expanding its Scientific Advisory Board and clinical development capabilities as it accelerates toward the clinic. The company operates as a platform-based therapeutics developer and is currently pre-revenue.
View full company profileTherapeutic Areas
Other Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| ABD-3001 | Advanced Biodesign | Phase 1 |
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |
| AV-MEL-1 | AIVITA Biomedical | Phase 1B |
| Melanoma Immunotherapy | Vaccizone | Pre-clinical |
| Melanoma Monitoring Solution | Oncobit | Commercial |
| Undisclosed Enhanced Antibody Program | Score Pharma | Pre-clinical |
| ASO for Melanoma | Carnation Therapeutics | Pre-clinical |
| Personalized DNA Cancer Vaccine | Neomatrix | Pre-clinical |
| Cannabics® MLN-33 | CNBX Pharmaceuticals | Preclinical |